GW685698/GW642444

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

AsthmaPulmonary Disease, Chronic Obstructive

Phase 2

A Study To Assess Single Dosage Strength Of GW685698/GW642444 Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT00731822

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2008-08-31End: 2009-02-28Updated: 2016-12-08

Phase 3

Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry

CompletedNCT01498653

GlaxoSmithKlineAsthma

Start: 2012-01-31End: 2013-02-28Updated: 2017-01-09

Related Papers

Efficacy and safety of 4 weeks' treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial.

2012-01-1932 citations